[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toxicant-exposure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toxicant-exposure":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100610350",false,"NCT07226440","Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)","Assessing the Impact of a Bile Acid Sequestrant on Serum PFAS Levels in Highly Exposed Individuals","ENGINE","Inclusion Criteria:\n\n* Male firefighter, active or retired\n* California resident\n* Age 18 or older\n* English-speaking\n* Access to a reliable internet connection\n* Willing to attend 3 in-person study visits in the San Francisco Bay Area over about 6.5 months\n* Willing to receive weekly text message reminders to complete online surveys\n* Willing to complete a mail-based, at-home finger-prick blood test\n* Willing to take 3 tablets (each tablet about the size of a multivitamin) orally twice daily for a total of 6 months\n* Evaluated by study team to have an elevated risk of PFAS exposure (e.g., duration of firefighting service, prior NASEM-7 result greater than or equal to 10 ng\u002FmL)\n\nExclusion Criteria:\n\n* Gastroparesis or other severe gastrointestinal motility disorders\n* Bowel obstruction\n* History of major gastrointestinal tract surgery\n* Dysphagia or difficulty swallowing (due to tablet size)\n* History of hypertriglyceridemia (triglycerides exceeding 500 mg\u002FdL)\n* History of hypertriglyceridemia-induced pancreatitis\n* Type 1 or 2 diabetes\n* History of fat-soluble vitamin deficiencies, i.e., vitamins A, D, E, or K\n* Phenylketonuria\n* History of known bleeding\u002Fclotting disorders\n* Medications or treatments that may impact the excretion of PFAS, such as activated charcoal, other bile acid sequestrants, chelation therapies, etc.\n* Unalterable plans to donate blood or plasma during the study participation period","MALE","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental toxicant and mold mycotoxin levels.",[27,28,29],"Toxicant Exposure","Firefighter","Occupational Exposure to Chemicals",[31,32,33,34,35,36],"Per- and polyfluoroalkyl substances","PFAS","Firefighters","Occupational exposure","Bile acid sequestrants","Colesevelam","RECRUITING","2026-04-22",{"date":40,"type":41},"2026-04-24","ACTUAL",{"date":43,"type":41},"2026-03-01",{"date":45,"type":20},"2028-12",{"name":47,"class":48},"University of California, San Francisco","OTHER",""]